This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss
by Zacks Equity Research
Cyclacel Pharmaceuticals (CYCC) delivered earnings and revenue surprises of 66.67% and 0%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Adherex Technologies Inc. (FENC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Adherex Technologies (FENC) delivered earnings and revenue surprises of -61.54% and 23.61%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of 26.19% and 3.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Harmony Biosciences (HRMY) delivered earnings and revenue surprises of 23.44% and 1.12%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Cyclacel Pharmaceuticals (CYCC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cyclacel Pharmaceuticals (CYCC) delivered earnings and revenue surprises of 13.25% and 86.67%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of 14.63% and 72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of -17.24% and 17.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of 15.94% and 119.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cyclacel Pharmaceuticals (CYCC) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Cyclacel Pharmaceuticals (CYCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy
by Zacks Equity Research
Cyclacel Pharmaceuticals (CYCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
New Strong Buy Stocks for October 17th
by Zacks Equity Research
MNTX, PGNY, GFF, RKDA and CYCC have been added to the Zacks Rank #1 (Strong Buy) List on October 17, 2023.
Cyclacel Pharmaceuticals, Inc. (CYCC) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Cyclacel Pharmaceuticals, Inc. (CYCC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued strength in Aurora Cannabis' (ACB) domestic adult recreational segment is expected to have driven Q1 sales.
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Interventional segment and Life Sciences segment's base business is expected to have driven Q4 sales.
Here's What to Expect Ahead of Wix's (WIX) Q3 Earnings Release
by Zacks Equity Research
Wix's (WIX) Q3 performance is likely to have benefited from strong bookings growth and an improvement in the user base. Forex volatility and weakness in global macroeconomic conditions are likely to have acted as headwinds.
Bionano (BNGO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Bionano Genomics (BNGO) is expected to provide updates on its earnings and revenues when it reports first-quarter 2021 result.
Cyclacel (CYCC) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on its pipeline progress when Cyclacel (CYCC) reports Q2 results.
Company News for Apr 21, 2020
by Zacks Equity Research
Companies In The News Are: CYCC, CODX, NBY, EXEL
Cyclacel (CYCC) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect Cyclacel (CYCC) to provide updates on its pipeline when it releases fourth-quarter 2019 results.
Company News for April 11, 2017
by Zacks Equity Research
Companies in the News are: SWFT,KNX,WFM,STRP,T,CYCC